Ainos, Inc.
- Open
- 1.64
- Day high
- 1.67
- Day low
- 1.63
- Prev close
- 1.58
- Volume
- 17K
- Mkt cap
- $12M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.7
- P/S
- 898.6
- Yield
- —
- Per share
- —
- ▲Insiders net buying $7K over the last 3 months (1 open-market buy, 0 sales)
- 🏛Institutions reducing (13F)
Ainos, Inc. (AIMD) is a Healthcare company listed on NASDAQ. The stock is down 59% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 0 sales (SEC Form 4).
Ainos, Inc. (AIMD) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
AIMD earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 3, 2026 | — | $-0.62 | — | $152 | — |
| May 13, 2026 | — | $-0.41 | — | $161 | — |
| Mar 30, 2026 | — | $-0.85 | — | $11120 | — |
| Nov 13, 2025 | — | $-0.64 | — | $2167 | — |
| Aug 13, 2025 | — | $-0.99 | — | $4663 | — |
| Mar 7, 2025 | — | $-1.30 | — | — | — |
| Mar 8, 2024 | — | $-1.37 | — | $19904 | — |
| Aug 11, 2023 | — | $-3.00 | — | $28555 | — |
| May 12, 2023 | — | $-3.25 | — | $49164 | — |
| Mar 31, 2023 | — | $-2.75 | — | $1M | — |
| Aug 15, 2022 | — | $-0.25 | — | $636627 | — |
| May 16, 2022 | — | $-3.75 | — | $87200 | — |
AIMD insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 9, 2026 | chiang yao-chungdirector | Buy | 3,500 | $2.05 |
| Jun 5, 2026 | chiang yao-chungdirector | Buy | 2,000 | $2.13 |
| Jun 1, 2026 | chiang yao-chungdirector | Buy | 250 | $2.30 |
| May 29, 2026 | chiang yao-chungdirector | Buy | 2,000 | $2.00 |
| May 27, 2026 | Taiwan Carbon Nano Technology Corp10 percent owner | Sell | 41,000 | $2.36 |
| May 27, 2026 | TSAI CHUN-JUNGdirector | Sell | 1,082 | $1.55 |
| May 27, 2026 | TSAI CHUN-JUNGdirector | Sell | 27,718 | $1.87 |
| May 27, 2026 | lee ting-chuandirector | Sell | 109,988 | $1.90 |
| May 26, 2026 | lee ting-chuandirector | Sell | 9,000 | $1.56 |
| May 26, 2026 | lee ting-chuandirector | Sell | 9,302 | $1.57 |
| May 20, 2026 | chiang yao-chungdirector | Buy | 500 | $1.65 |
| May 20, 2026 | chiang yao-chungdirector | Buy | 2,200 | $1.68 |
| May 7, 2026 | chiang yao-chungdirector | Buy | 129 | $1.70 |
| May 1, 2026 | chiang yao-chungdirector | Buy | 200 | $1.68 |
| May 1, 2026 | chiang yao-chungdirector | Buy | 100 | $1.75 |
Source: AIMD SEC Form 4 filings, latest Jun 9, 2026. For informational purposes only — not investment advice.
See the full AIMD insider & 13F page →Ainos, Inc. company profile
Overview
Ainos, Inc. (NASDAQ:AIMD) is a biotechnology company founded in 1984 and headquartered in San Diego, California. Originally incorporated as Amarillo Biosciences, Inc., the company rebranded to Ainos in May 2021 and went public through an IPO in January 2021. The company operates in the healthcare sector, focusing on developing medical technologies for point-of-care diagnostic testing and novel therapeutic treatments for various disease indications.
Business
Ainos operates in the biotechnology industry, specifically focusing on two main areas: diagnostic testing solutions and therapeutic drug development. The biotechnology sector involves companies that use biological processes, organisms, or systems to manufacture products intended to improve human health and medicine. The company's core offerings include several distinct product lines. Their COVID-19 testing solutions comprise antigen rapid test kits paired with a cloud-based test management platform that includes both personal and enterprise applications. This represents a point-of-care testing approach, which means diagnostic tests that can be performed at or near the site of patient care rather than in centralized laboratories. The company also develops nucleic acid tests for COVID-19, which are molecular diagnostic tests that detect the genetic material of the virus. Beyond COVID-19 testing, Ainos is developing volatile organic compounds (VOC) point-of-care testing technology. VOCs are chemicals that can be found in breath and may serve as biomarkers for various diseases, offering a non-invasive diagnostic approach. On the therapeutic side, the company is advancing Very Low-Dose Oral Interferon Alpha, which is based on interferon-alpha's broad treatment applications. Interferons are proteins naturally produced by the immune system to fight infections and diseases. The company is also developing a Synthetic RNA (SRNA) technology platform in Taiwan, which involves creating artificial RNA molecules that could potentially be used for therapeutic purposes. The company's revenue has been minimal, with most recent quarters showing zero revenue except for Q1 2025 which recorded $106,207 in revenue, suggesting the diagnostic testing segment may be generating some commercial activity while therapeutic products remain in development stages.
Revenue model
Ainos generates revenue primarily through product sales of its diagnostic testing solutions, particularly COVID-19 test kits and associated cloud-based management services. The company's business model appears to be transitioning from a pure research and development phase to early commercialization, as evidenced by the recent revenue generation in Q1 2025 after several quarters of zero revenue. The paying customers for Ainos' diagnostic products include healthcare providers, enterprises requiring employee testing, and potentially individual consumers through the personal application component of their testing platform. The cloud-based test management system suggests a potential subscription or service fee component to their revenue model, though specific pricing details are not available from the financial data. Several factors could significantly impact the company's margins and revenue potential. Regulatory approval processes represent a major factor, as biotechnology products require extensive testing and approval from agencies like the FDA before they can be marketed. Competition from established diagnostic companies and larger pharmaceutical firms could pressure pricing and market share. The pandemic-driven demand for COVID-19 testing has likely been a temporary boost, but as the pandemic subsides, demand for these products may decline significantly. Manufacturing and supply chain costs for both diagnostic kits and therapeutic compounds can substantially impact margins, particularly for a smaller company without economies of scale. Research and development expenses remain substantial, as evidenced by the company's consistent operating losses, and successful product development could eventually lead to higher-margin therapeutic sales. Intellectual property protection and potential licensing opportunities could provide additional revenue streams, while healthcare reimbursement policies could affect customer adoption and willingness to pay for their diagnostic solutions.
Competitive moat
Ainos operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages. The company's potential moat primarily stems from its intellectual property portfolio around its specific formulations and technologies, particularly the Very Low-Dose Oral Interferon Alpha and Synthetic RNA platform. However, these technologies are still in development phases and have not yet demonstrated clear clinical superiority or market acceptance. The company's cloud-based test management platform could provide some competitive differentiation in the diagnostic testing space by offering integrated digital solutions, but this advantage is relatively weak as larger technology and healthcare companies can easily develop similar platforms with greater resources. The biotechnology industry is characterized by intense competition from well-funded pharmaceutical giants, specialized biotech firms, and academic research institutions. Major pharmaceutical companies like Roche, Abbott, and Pfizer have significantly more resources for research, development, and market penetration. Emerging biotechnology companies with similar focus areas pose competitive threats, particularly those with stronger financial backing or more advanced clinical trial progress. Regulatory barriers provide some protection by making market entry expensive and time-consuming, but these same barriers also pose significant risks to Ainos' own product development. The company's small size and limited financial resources make it vulnerable to being outcompeted by larger players who can sustain longer development cycles and more extensive clinical trials. Overall, Ainos' competitive moat appears weak, with the company's success heavily dependent on successful clinical development and regulatory approval of its therapeutic candidates, areas where many biotechnology companies fail despite promising early-stage results.
Risks & safety
The margin of safety for Ainos appears concerning given its early-stage development status and cash burn rate. • Cash position and burn rate: The company holds $2.6 million in cash and short-term investments as of Q1 2025, down from $3.9 million in Q4 2024. With quarterly operating cash flow losses of approximately $1.2 million, the company has roughly 2 quarters of operating runway at current burn rates. • Debt and solvency: Current ratio of 2.0 indicates adequate short-term liquidity, but the debt-to-equity ratio of 0.91 shows significant leverage. The company has been consistently unprofitable with net losses exceeding $3 million per quarter. • Valuation metrics: Trading at 0.59x book value and negative earnings multiples due to losses. The enterprise value to EBITDA ratio is negative due to negative EBITDA, making traditional valuation metrics less meaningful. • Other considerations: The company's market capitalization of approximately $14 million is extremely small, making it susceptible to high volatility. Revenue generation remains minimal and inconsistent, with the business model still largely unproven in commercial markets.
Recent development
Based on the available financial data, Ainos has undergone significant strategic evolution over recent years. The company's revenue pattern shows a dramatic shift from $3.5 million in 2022 to minimal revenue in 2023-2024, followed by a small recovery to $106,207 in Q1 2025. This suggests the company may have pivoted away from whatever was generating revenue in 2022 (likely COVID-19 testing during peak pandemic demand) toward developing its therapeutic pipeline. The company's cash position has been declining steadily, from over $8 million in Q2 2024 to $2.6 million in Q1 2025, indicating intensive research and development spending. The consistent negative EBITDA ranging from -$1.8 million to -$4.5 million per quarter reflects ongoing investment in product development rather than commercial operations. The rebranding from Amarillo Biosciences to Ainos in May 2021, coinciding with the IPO, suggests a strategic repositioning to focus on the current product portfolio. The development of the cloud-based test management platform represents an attempt to create a more comprehensive diagnostic solution beyond simple test kits, potentially targeting the growing digital health market. The company's focus on multiple therapeutic modalities - from interferon-based treatments to synthetic RNA technology - indicates a diversified approach to drug development, though this also spreads limited resources across multiple programs. The establishment of operations in Taiwan for the SRNA platform suggests international expansion of research capabilities.
AIMD company profile · for informational purposes only — not investment advice.
Track AIMD with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free